Johnson & Johnson
Johnson & Johnson Director Retirement and Annual Meeting Results
Summary
Johnson & Johnson announced that D. Adamczyk will retire from the Board of Directors effective May 31, 2025, for personal reasons. The 2025 Annual Meeting of Shareholders resulted in the election of all 11 Director nominees, approval of executive compensation, ratification of PricewaterhouseCoopers LLP as the independent auditor, and the rejection of proposals for voting on excessive golden parachutes and a human rights impact assessment.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement